Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Correction of hemostatic abnormalities and portal pressure variations in patients with cirrhosis.

Giannini EG, Stravitz RT, Caldwell SH.

Hepatology. 2014 Oct;60(4):1442. doi: 10.1002/hep.27029. Epub 2014 Aug 25. No abstract available.

PMID:
24452495
2.

Portal vein thrombosis in cirrhosis: ignore, prevent, or treat?

Senzolo M, Caldwell S.

Gastroenterology. 2013 Feb;144(2):e19-20. doi: 10.1053/j.gastro.2012.11.036. Epub 2012 Dec 21. No abstract available.

PMID:
23261888
3.

Anticoagulation in cirrhosis: ready … set … wait!

Seijo S, Garcia-Pagan JC.

Hepatology. 2013 Sep;58(3):1175-6. doi: 10.1002/hep.26503. Epub 2013 Jul 29. No abstract available.

PMID:
23703896
4.

Reply: To PMID 22819864.

Villa E, Cammà C, Valla D.

Gastroenterology. 2013 Feb;144(2):e20. doi: 10.1053/j.gastro.2012.12.023. Epub 2012 Dec 21. No abstract available.

PMID:
23266379
5.

Prophylactic anticoagulation in cirrhotics: a paradox for prime time?

Fontana RJ.

Gastroenterology. 2012 Nov;143(5):1138-41. doi: 10.1053/j.gastro.2012.09.020. Epub 2012 Sep 20. No abstract available.

PMID:
23000228
6.

Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.

Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, Zecchini R, Gitto S, Petta S, Lei B, Bernabucci V, Vukotic R, De Maria N, Schepis F, Karampatou A, Caporali C, Simoni L, Del Buono M, Zambotto B, Turola E, Fornaciari G, Schianchi S, Ferrari A, Valla D.

Gastroenterology. 2012 Nov;143(5):1253-60.e1-4. doi: 10.1053/j.gastro.2012.07.018. Epub 2012 Jul 20.

PMID:
22819864
7.

How does bacterial DNA induce liver failure in cirrhosis?

Fujita T.

Hepatology. 2009 Apr;49(4):1393; author reply 1393-4. doi: 10.1002/hep.22814. No abstract available.

PMID:
19330865
8.

[Enoxaparin in haemodialysis].

Olszowska A, Zelichowski G.

Pol Merkur Lekarski. 2002 Nov;13(77):433-6. Review. Polish.

PMID:
12621768
9.

Management of portal vein thrombosis in liver cirrhosis.

Qi X, Han G, Fan D.

Nat Rev Gastroenterol Hepatol. 2014 Jul;11(7):435-46. doi: 10.1038/nrgastro.2014.36. Epub 2014 Apr 1. Review.

PMID:
24686266
10.

[Introduction to the study of thrombosis of the portal vein].

LEGER L.

J Int Coll Surg. 1955 May;23(5 Section 1):603-11. French. No abstract available.

PMID:
14381634
11.

Emergency anticoagulation treatment for cirrhosis patients with portal vein thrombosis and acute variceal bleeding.

Maruyama H, Takahashi M, Shimada T, Yokosuka O.

Scand J Gastroenterol. 2012 Jun;47(6):686-91. doi: 10.3109/00365521.2012.674972. Epub 2012 Apr 4.

PMID:
22472055
12.

No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.

Mortensen C, Karlsen S, Grønbæk H, Nielsen DT, Frevert S, Clemmesen JO, Møller S, Jensen JS, Bendtsen F.

Liver Int. 2013 Oct;33(9):1309-15. doi: 10.1111/liv.12205. Epub 2013 Jun 14.

PMID:
23763259
13.

Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin.

Brennand JE, Walker ID, Greer IA.

Acta Haematol. 1999 Mar;101(1):53-5. No abstract available.

PMID:
10085440
14.

Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis.

Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, Romano L, Balzano A.

J Clin Gastroenterol. 2010 Jul;44(6):448-51. doi: 10.1097/MCG.0b013e3181b3ab44.

PMID:
19730112
15.

Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin.

Rostoker G, Durand-Zaleski I, Petit-Phar M, Ben Maadi A, Jazaerli N, Radier C, Rahmouni A, Mathieu D, Vasile N, Rosso J, et al.

Nephron. 1995;69(1):20-8.

PMID:
7891793
16.

Prosthetic heart valves and pregnancy.

McLintock C, North RA, White HD.

Circulation. 2003 Dec 9;108(23):e159-60; author reply e159-60. No abstract available.

17.

Progressive thrombosis in a 13-year-old girl with trisomy 21 under therapy with low molecular weight heparin.

Karow A, Hainmann I, Nakamura L, Budde U, Mueller C, Zieger B.

Klin Padiatr. 2011 May;223(3):180-1. doi: 10.1055/s-0031-1275338. Epub 2011 Apr 6. No abstract available.

PMID:
21472634
18.

Use of enoxaparin to diminish the incidence of vascular access stenosis/thrombosis in chronic hemodialysis patients.

Shavit L, Lifschitz M, Lee S, Slotki I.

Int Urol Nephrol. 2011 Jun;43(2):499-505. doi: 10.1007/s11255-009-9703-1. Epub 2010 Jan 10.

PMID:
20063059
19.

Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty.

Colwell CW Jr, Spiro TE.

Clin Orthop Relat Res. 1995 Oct;(319):215-22.

PMID:
7554633
20.

JAK2 exon 12 mutations were not found in liver transplant recipients with or without pretransplant portal vein thrombosis.

Ayala R, Rapado I, Grande S, Moreno E, Martínez-López J.

Eur J Gastroenterol Hepatol. 2014 Mar;26(3):362-3. doi: 10.1097/MEG.0000000000000022. No abstract available.

PMID:
24463542
Items per page

Supplemental Content

Write to the Help Desk